Jumping the pricing gun?

CAR T companies clawed back last Friday after losing a combined $1.6 billion in market cap on Thursday following a comment by Kite Pharma Inc. (NASDAQ:KITE) CFO Cynthia Butitta on the potential pricing for the cancer immunotherapies. And two buysiders don't expect the comments to matter if the CAR T players are able to replicate efficacy data seen in early trials.

In an interview with Reuters, Butitta said Kite's models for its chimeric antigen receptor (CAR) T cell therapies set a base case price at $150,000 per treatment, but the actual price would depend on survival rates and other efficacy measures. ...